| 7 | | ZOOM meeting: ** https://cern.zoom.us/j/95417789956?pwd=Nk9DZmwxc3R0SjdScjlVeEFrRlRwdz09** |
| | 7 | 1. **[wiki:Research/DesignStudy/SteeringGroup/2020-07-03 Notes of last meeting and actions arising:]** |
| | 8 | * **KL**: Set up series of meetings with leads at partner organisations to discuss preparation of R&D programme. |
| | 9 | - **Superceded.** |
| | 10 | * **KL/CB**: Consider meeting between Imperial (and other) ion-accelerator experts with the relevant experts in CLF. |
| | 11 | - **Ongoing.** |
| | 12 | * **KL/KK**: to collaborate on the development for a proposal for such a meeting on the timescale of November 2020. |
| | 13 | - **Ongoing.** |
| | 14 | * **KL**: Ensure one representative per group at the next LhARA SG meeting. |
| | 15 | - **Stands.** |
| | 16 | * **KL**: Raise NIHR engagement with K.Gleeson. |
| | 17 | - **Done.** |
| | 18 | * **KL**: Seek PPI representative for SG. |
| | 19 | - **Done.** Welcome G. Jones and H. Hall. |
| | 20 | * **KK, JPar, CW, KL**: Make relevant contact with local PPI groups as described in item 4. |
| | 21 | - StG: Brm is not a radiotherapy research centre. Shoudl contact Manchester, Oxford, and Liverpool. |
| | 22 | - TG: Also need to contact with relevant medical physics groups. |
| | 23 | * **KL&JPar**: Write to CTRAD w/s 4 chair (KK) to ask how we might work together to raise awarenents of our programme among the patient and clinician communitites. |
| | 24 | - **Done.** Letter written and sent, see under clinician engagement below. Revised action needs to be agreed. |
| | 25 | * **KK, JPar, CW, KL, SG**: Make relevant contact with local clinician groups as described in item 4. |
| | 26 | - **Ongoing.** |
| | 27 | * **KL**: Write to J.Clarke to ask for support to reach out to relevant industry. |
| | 28 | - **Stands.** |
| | 29 | * **PA**: Make contact with MTC to see how to make contact with relevant industry. |
| | 30 | - Stands |
| | 31 | * **PA/KL** will cooperate in drafting a letter. |
| | 32 | - **Stands.** |
| | 33 | * **KL**: Review proposed w/p structure and skills matrix taking into account comments under item 4. |
| | 34 | - **Stands. |
| | 35 | * **KL/RMcL**: Liaise to generate small group to coordinate development of instrumentation aspects of the programme. |
| | 36 | - **Done.** Meeting organised between A.Price and R.McLauchlan a success. |
| | 37 | |
| | 38 | 2. **[raw-attachment:2020-09-24-Update-Long.pptx Update on progress]: KL** \\ |
| | 39 | |
| | 40 | 3. **[raw-attachment:LhARA-PPI-Strategy-DRAFT-HH-GJ-version-05Sep20.pdf Towards a PPI strategy for LhARA]: GJ, HH** \\ |
| | 41 | - Main stem of strategy is to raise awareness with public and with patients. Then develop the engagement as the programme progresses. |
| | 42 | - Hard to see anything which would not benefit patients and also the health services. Patient input is vital all at all stages in the development of the programme. |
| | 43 | - Management of PPI will take time. Perhaps means that we need to include some resource. Marsden PPI outreach. |
| | 44 | - HH sits on various PPI advisory groups and can make links top various institutes. |
| | 45 | - Focus on engagement rather than involvement. |
| | 46 | - StG: |
| | 47 | - Agrees re effort involved in getting broad activity. Link to the Royal Marsden will be important. |
| | 48 | - KK: |
| | 49 | - BRC links important. |
| | 50 | - SG expressed it grateful recognition of the efforts of GJ and HH and the PPI representatives in drafting the two Lay Summaries so far. Both are/will be published. |
| | 51 | |
| | 52 | 4. **Towards a clinician-engagement strategy for LhARA: StG** \\ |
| | 53 | - Neil Burnett and Adrian Crellin from Brm meeting might be pursuared to promote activity. Elizabeth Schuster, Rostoc is a researcher into the impact of microbeams. |
| | 54 | - There is a need to reach out to research-active clinicians. Probably should build up a target list in preparation for a webinar. A process such as that adopted by TP for the endstation/diagnostics development would be appropriate. |
| | 55 | - KK: |
| | 56 | - Noted the perception in the community that laser-ion beams are like nuclear fusion -- always 15 years away. |
| | 57 | - Critical to develop clear statement of what what the laser-hybrid technique can do that others cant. |
| | 58 | - Meeting: |
| | 59 | - We agreed to work towards a meeting of the relevant peer groups. TKW agreed to make contact with IoP at "top level". |
| | 60 | |
| | 61 | 5. **[https://epsrc.ukri.org/funding/calls/second-call-for-transformative-healthcare-technologies-deveopment-phase/ Transformative Healthcare Technologies second call]: KL/All** \\ |
| | 62 | [raw-attachment:2020-09-24-LhARA-THT-skel-d0.2.pdf Updated outline presented at the LhARA weekly meeting 22Sep20] \\ |
| | 63 | Discussion included: |
| | 64 | - PPI: GJ/HH |
| | 65 | - Clinician engagement: StG |
| | 66 | - Plan for preparation of proposal |
| | 67 | - Scope |
| | 68 | - Work packages |
| | 69 | - Stakeholders |
| | 70 | |
| | 71 | 6. **DONMs** \\ |
| | 72 | * TBD |
| | 73 | |
| | 74 | 7. **AoB** \\ |
